Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
November 21, 2024 08:00 ET
|
Science 37, Inc.
Science 37 contributes almost half (47%) of the U.S. enrollment for GSK Phase 3 rare disease study while bolstering participant retention figures.
Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
July 18, 2024 08:00 ET
|
Science 37, Inc.
Science 37 enrolls 65 patients per month for its sponsor's Phase 3 infectious disease clinical trial.
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
June 27, 2024 09:41 ET
|
Science 37, Inc.
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities.
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024 15:55 ET
|
Science 37, Inc.
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024 08:00 ET
|
Science 37, Inc.
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
May 13, 2024 08:00 ET
|
Science 37, Inc.
Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
May 02, 2024 08:00 ET
|
Science 37, Inc.
Science 37's Metasite™ and Patient Recruitment Solutions together dramatically boost patient enrollment in a Phase 3 asthma clinical trial.
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
April 17, 2024 08:00 ET
|
Science 37, Inc.
Science 37's Patient Recruitment Solution provides fully-consented patients to clinical trial sites to supplement enrollment.
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
December 21, 2022 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking...
National Brain Tumor Society Launches New Brain Tumor-Specific Clinical Trial Finder
March 22, 2017 08:30 ET
|
National Brain Tumor Society
BOSTON, MA--(Marketwired - March 22, 2017) - National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, today announced the launch of the...